Princess Alexandra Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2021

  1. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 5, pp. 643-654